An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

Trial Profile

An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs CCX 140 (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 09 Oct 2018 Status changed from planning to recruiting.
    • 20 Jan 2017 New trial record
    • 09 Jan 2017 According to a ChemoCentryx media release, the company expects to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top